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Abstract
We have previously shown that both chloroquine and paracetamol (acetaminophen) have antipyretic activity during treatment of
acute uncomplicated Plasmodium falciparum malaria in children 1–4 years old. Here, we studied if this effect was accompanied by
changes in plasma cytokine levels.
The 104 children were treated with either chloroquine or sulfadoxine/pyrimethamine (SP) alone, SP + chloroquine or
SP + paracetamol for 4 days. Cytokine levels were determined days 0, 2 and 3, body temperature every sixth hour until 72 h
and parasitemia once daily for 4 days.
At admission, body temperature correlated with levels of IL-10, IFN-␥ and IL-6, and parasitemia correlated with IL-10 and IL-6.
Except for TNF-␣ and IL-1␤, where no significant effect was found, all cytokine levels (IL-10, IFN-␥, IL-6, IL-12, IL-13, IL-18
and IL-4) decreased up to day 2 (p < 0.05). IL-6 levels continued to fall from days 2 to 3 (p < 0.05), whereas increased levels were
found for several cytokines (IL-12, IL-13, IL-18 and IL-1␤) (p < 0.05).
The antipyretic effects of chloroquine and paracetamol could not be related to any specific changes in the evaluated cytokine
production or in Th1/Th2 or inflammatory/anti-inflammatory cytokine ratios. Alternative mechanisms for antipyretic effects and
associations between fever and cytokine levels during uncomplicated P. falciparum malaria are therefore discussed.
© 2006 Elsevier B.V. All rights reserved.
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1. Introduction
Fever is the most common indicator of disease in
human malaria, but the mechanisms for its induction and
regulation during the disease is not clear. From studies
with the bacterial product LPS, it has for many years
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been thought that fever is induced via the intermediate
production of pyrogenic cytokines (IL-1, TNF-␣, IL-6,
IL-8, MIP-1␤, and IFN-␥) and that the height and magnitude of fever is a sum of the interactions of pyrogenic
cytokines and endogenous antipyretics (IL-10, AVP and
glucocorticoids) (Leon, 2002). However, the concept
is challenged by findings indicating that fever during
infection can occur independently of cytokine production (Dinarello, 2004). Toll-like receptor (TLR) signal
transduction provides an explanation by which microbial
products can cause fever directly on the vascular network
supplying the thermoregulatory centre in the anterior
hypothalamus. Thus, fever during an infection is now
thought to be a result of both cytokine and TLRs (or other
receptors) ligand activity, followed by cyclooxygenase2, prostaglandin E2 (PGE2 ) production and activation of
hypothalamic PGE2 receptors.
There are several relations that indicate a pivotal role
for pro-inflammatory cytokines in induction of malarial
fever. Malaria parasite derived glycosylphosphatidylinositol (GPI) induces TNF and IL-1 in macrophages and
causes pyrexia in mice models (Schofield and Hackett,
1993). Elevated plasma levels of TNF, IL-6 and IFN-␥
are detected during uncomplicated Plasmodium falciparum malaria compared to asymptomatic infections
(Mshana et al., 1991; Anstey et al., 1996; Othoro et
al., 1999). For the cytokines IL-1␤, IL-4, IL-12, IL13 and IL-18 the information is less clear, or so far
missing (Mshana et al., 1991; Othoro et al., 1999;
Chaisavaneeyakorn et al., 2003). Plasmodium vivax
fever episodes appear with 48 h intervals coinciding with
increased serum levels of TNF (Karunaweera et al.,
1992). In human cerebral malaria, fever was reduced
by injection of anti-TNF antibodies (Kwiatkowski et al.,
1993). This does however not exclude the possibility that
at least a part of the fever induction in non-complicated
P. falciparum malaria is cytokine independent.
We have previously shown that the antimalarial drug
chloroquine exerts antipyretic effects, equal to paracetamol, during treatment of uncomplicated P. falciparum
malaria (Hugosson et al., 2003). Chloroquine inhibits
production of several pro-inflammatory cytokines and
enhances IL-10 production in human in vitro assays
(Hugosson et al., 2002; Picot et al., 1993; Ertel et al.,
1991; Landewe et al., 1992; van den Borne et al., 1997;
Karres et al., 1998; Jeong and Jue, 1997). The protection of rats challenged by lethal doses of CpG and LPS
by chloroquine treatment is associated with decreases in
serum levels of TNF-␣ and IL-6 (Hong et al., 2004). It
is therefore reasonable to believe that chloroquine could
inhibit malarial fever by altering the levels and the balance of the cytokine response during malaria infections.

However, recent evidence suggests that chloroquine can
block signalling via TLRs (Lee et al., 2003; Zou et
al., 2003), which provides a possible mechanism for
a cytokine independent mechanism for the antipyretic
activity of chloroquine.
In order to study the role of pro- and anti-inflammatory cytokines in relation to fever and in chloroquine
induced antipyresis, we compared cytokine levels before
and during treatment of acute uncomplicated P. falciparum malaria. We investigated differences between four
drug regimes generating different effects on the body
temperature.
2. Methods
2.1. Study area
The study was carried out in Kibaha District Hospital
40 km north-west of Dar es Salaam, Tanzania, an area
holoendemic for malaria with largely perennial transmission of mainly P. falciparum.
2.2. Study patients
Data and samples in this work are obtained from
patients included in a study designed to compare
antipyretic, parasitological and immunulogical effects of
four different antimalarial treatment regimes (Hugosson
et al., 2003). Children between 12 and 59 months
of age attending the primary health care unit of the
hospital, between 3 July and 20 August 1998, were
included in the study, if they fulfilled the inclusion criteria of uncomplicated mono-infection with P. falciparum
(2000–250 000 parasites/mL, axillary temperature 37.5–
40.0 ◦ C). Children were not considered for the study
if they had altered level of consciousness, convulsions, prostration, circulatory shock or respiratory distress, hyperparasitemia (>250 000 parasites/L), severe
anaemia (haemoglobin levels below 5.0 g/dL) or suspected coexisting diseases. The guardians of the children, were asked for their informed consent before the
children were enrolled in the study. Ethical clearance
was provided by the Ministry of Health, Tanzania and by
clinical research committee of the Karolinska Institutet,
Stockholm, Sweden. A more detailed information about
the patients is provided in a previous report (Hugosson
et al., 2003).
2.3. Drug administration
At admission to the hospital, the patients were
consecutively divided into either of four treatment
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groups, according to a predetermined schedule: (1)
chloroquine alone, (2) sulfadoxine/pyrimethamine (SP)
alone, (3) SP + chloroquine, and (4) SP + paracetamol.
The three drugs were given as follows: (a) chloroquine phosphate (F Hoffman-La Roche, Basel, Switzerland) 10 + 10 + 5 mg base/kg body weight (BW) over
a period of 3 days, (b) SP (Fansidar® , F HoffmanLa Roche, Basel, Switzerland) single dose of 1.25 mg
pyrimethamine and 25 mg sulfadoxine/kg BW, and (c)
paracetamol, 15 mg/kg BW every 8 for 72 h. All treatments started at 3–4 p.m. on the day of admission and
were given under close supervision by the research team.
No antipyretic drugs were given to the children apart
from the treatment schedule defined above. Mechanical
antipyresis (tepid sponging and electric fanning) was to
be considered during episodes of high fever (>39 ◦ C).
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were purchased from R&D systems (Abingdon, United
Kingdom). Blocking antibodies were: mouse Ig (1DIK
or 9D7) (MABTECH, Stockholm, Sweden) or normal
goat IgG (AB-108-C).
2.6. Cytokine determinations

Venous blood samples were taken on day 0 (before
start of treatment) (=T0 ) and on day 2 (=T2 ) and 3 (=T3 ),
respectively. After centrifugation, the plasma was immediately aliquoted and stored at −30 ◦ C during the time of
the study (at the most 2 months) and thereafter at −70 ◦ C
until transferred on dry ice before being finally stored at
−70 ◦ C until analysed year 2000. Axillary body temperature was measured at attendance to the primary health
care unit to the hospital, at start of treatment (T0 ) and
then every 6 up to 72 h. Parasite species was assessed in
Giemsa-stained thin blood smears at admission. Parasite
densities were estimated, in thick smears, by counting
asexual parasites per 200 leucocytes. This was performed
before admission and every 24 up to 72 h. Out of 169
patients who participated in the study until 72 h, samples from 104 patients, equally distributed between the
four treatment groups (21 in each group), were randomly
selected for cytokine analyses.

The cytokines were analysed by sandwich ELISAs.
Briefly, half-area ELISA plates (Corning Incorporated,
Corning, NY, USA) were coated over night at 4 ◦ C
with 25 L of catcher antibodies (1 g/mL). Phosphate
buffered saline (PBS) supplemented with 0.05% Bovine
serum albumin was used for blocking (90 min, at RT)
and for dilution of standards and samples. To reassure
specific binding, blocking antibodies were applied to
the plates immediately before addition of the samples
and standards. All test samples were coded and applied
randomly in duplicates (diluted 1:1) into the pre-coated
plates and incubated over night at 4 ◦ C. Bound cytokines
were assayed using biotinylated cytokine specific antibodies (for 2 h, at 37 ◦ C), followed by alkaline phosphatase (ALP)-conjugated streptavidin (MABTECH,
Stockholm, Sweden) diluted 1:1000 and incubated
(90 min, at RT). Thereafter the phosphatase substrate
(Sigma Diagnostics, St. Louis, MO, USA) was applied
and the optical density was read at 450 nm. Cytokine
concentrations were calculated from standard curves
obtained by incubating serial dilutions of the respective
recombinant cytokines (NIBSC, Hertfordshire, United
Kingdom or IL-18 from R&D systems, Abingdon,
United Kingdom). Standards were aliquoted and stored
at −70 ◦ C. The detection limits were set according to
the linear part of the standard curve and the background
values of buffer controls and were for: IL-1␤ 3–3000,
IL-4 10–3000, IL-6 30–10 000, IL-10 30–3000, IL-12
10–3000, IL-13 15–2000, IL-18 100–30 000, TNF-␣
30–4000 pg/mL and IFN-␥ 0.01–30 U/mL, respectively.

2.5. Antibodies used for cytokine determination

2.7. Calculations and statistics analysis

The following mouse antibodies against human
cytokines were used as catcher antibodies: IL-4 (82.4),
IL-6 (13A5), IL-10 (9D7), IL-12-I (p40 chain), IL-13I, IFN-␥ (1DIK) (MABTECH, Stockholm, Sweden),
IL-1␤ (ILB1-H6) (Endogen, Woburn, MA, USA) and
TNF-␣ (Mab1) (Pharmingen, San Diego, CA, USA).
Biotinylated antibodies used for detection were: IL4 (12.1), IL-6 (39C3), IL-10 (12G8), IL-12-II (p40
chain), IL-13-II, IFN-␥ (7-B6-1) (MABTECH, Stockholm, Sweden), IL-1␤ (ILB1-H67) (Endogen, Woburn,
MA, USA) and TNF-␣ (Mab11) (Pharmingen). Goat
antibodies against human IL-18 (52713.11 and BAF 318)

All correlations were analysed with the non-parametric Spearman rank order coefficient. In case of nondetectable levels a value of 1 (or 0.01 for IFN-␥) was
used. Ratios were calculated by dividing the cytokine
levels of two different cytokines. Comparison of plasma
cytokine levels between treatment groups was analysed
by Kruskal Wallis test for ranked median values. Comparisons between the cytokine levels at different time
points were analysed by Friedman ANOVA and the post
hoc test by Wilcoxon. Progression of cytokine responses
in the different treatment groups was calculated by subtracting the values (plasma levels or ratios) at the second

2.4. Sample collection and microscopy
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Table 2
Cytokine levels correlate with fever and parasitemia day 0 and day 2

time point from the first and the differences between
the treatment groups were compared by Kruskal Wallis test for ranked median values. Ratios in the different
treatment groups at different time points were compared
by Kruskal Wallis test for ranked medians. All statistical
tests were two sided with a significance level of p < 0.05.
The Bonferroni correction is sometimes used when testing multiple variables, since the more associations that
are studied, the greater likelihood of finding one that
exists solely due to chance. A higher threshold for statistical significance is calculated by dividing the current
threshold (p = 0.05) by the number of cytokines tested
((p = 0.05)/9), which gives (p = 0.006). The significance
of this correction is disputed in some circumstances, but
is included in the result part as a complement (Perneger,
1998).

Cytokine

Day 0

Day 2

R

p-Level

R

p-Level

Temperature
IL-10
IFN-␥
IL-6

0.38
0.25
0.23

<0.001
0.009
0.02

0.34
0.11
0.24

<0.001
0.3
0.01

Parasitemia
IL-6
IL-10

0.28
0.23

0.004
0.02

0.15
0.35

0.1
<0.001

Spearman rank order correlations (n = 104).

If the Bonferroni correction is used for multiple variable testing this would change the threshold for statistical
significance to p = 0.006, which would render the association between temperature and IFN-␥ to borderlineand temperature-IL-6 and parasitemia-IL-10 day 0 below
statistical significance. However, the likelihood of false
positive results because of multiple variable testing is
low, since there is a statistical significant association
between temperature and IL-6 and parasitemia and IL10, respectively, at both day 0 and day 2.

3. Results
3.1. Relationships between fever, parasitemia and
plasma levels of cytokines
Pre-treatment plasma levels and the frequencies of
detection of the nine cytokines tested are presented in
Table 1. Associations between cytokine levels, parasitemias and body temperatures are presented in Table 2.
Because of the fluctuations of the temperature over time,
a mean value was calculated from the measurement
before admittance and from that of start of treatment.
Strongest associations were found between body temperature and IL-10, IFN-␥ and IL-6 (Table 2). Significant
associations were also detected between parasitemia at
day 0 and plasma levels of IL-6 and IL-10 (Table 2). On
day 2, IL-10 and IL-6 levels still correlated with body
temperature and IL-10 levels with parasitemia (Table 2).

3.2. Effects of antimalarial treatment on plasma
cytokine levels
The median levels of the plasma cytokine levels did
not differ between the treatment groups at the start of
treatment or at day 2 or 3. However, there were major
inter-individual differences in cytokine levels. Different approaches were applied to analyse the effect of
the treatments, but no significant differences between
the treatment groups in the magnitude of changes in

Table 1
Frequencies and concentrations of cytokines obtained in plasma from 104 Tanzanian children during acute uncomplicated Plasmodium falciparum
malaria infections
Cytokine

IFN-␥
IL-10
IL-12
IL-13
IL-18
IL-1␤
IL-4
IL-6
TNF-␣
a
b

Frequencies of detection
(number)

Median cytokine concentration
among all patients (pg/mL)a

Median cytokine concentration among patients
with detectable cytokine levels (pg/mL)a

0b

2b

3b

0b

2b

3b

0b

2b

3b

81
104
104
51
72
81
62
57
42

65
100
104
42
54
75
52
41
36

70
94
104
47
66
86
60
32
50

0.18
500
370
0
590
21
165
98
0

0.09
200
300
0
230
23
0
0
0

0.10
120
340
0
470
27
13
0
0

0.24
500
370
120
1000
28
29
420
420

0.19
200
300
120
750
38
28
290
420

0.19
160
340
140
920
36
32
250
380

U/mL for IFN-␥.
Day of measure.
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cytokine levels with time, or in the number of individuals with increasing/decreasing plasma levels between
the time points were detected. A “balance” between
pro-inflammatory and anti-inflammatory cytokines is
thought to determine the outcome of disease. Ratios
between the different cytokines did not differ between
the treatment groups at any of the time points tested (not
listed). Nor did changes in ratio values between the time
points differ between the treatment groups (not listed).
3.3. Kinetics of cytokine levels in plasma during
treatment
Data from all individuals were pooled for the kinetic
analysis, since no differences were seen in cytokine levels between the treatment groups. From the start of the
treatment (T0 ), the median levels of all tested cytokines,
decreased significantly (p < 0.05, ANOVA for repeated
measure, Wilcoxon) up to day 2, except for TNF-␣ and
IL-1␤ for which no significant effect was found (Fig. 1).
IL-6 continued to fall from days 2 to 3 (p < 0.05) while
IL-12, IL-13, IL-18 and IL-1␤ all increased (p < 0.05).
Statistically significant net decreases in plasma levels
from days 0 to 3 were seen for IFN-␥, IL-10, IL-6 and
IL-4.

Fig. 1. Median cytokine levels during treatment of Plasmodium falciparum infection in 104 Tanzanian children.
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4. Discussion
We hypothesised that chloroquine decreases fever and
exhibit its anti-inflammatory effects by altering the levels and the balance of cytokine responses during malaria
infections. However, despite significant associations
between fever and plasma levels of several cytokines
and clear antipyretic effects of chloroquine and paracetamol, no differences were detected in cytokine levels
or ratios compared to those treated without antipyretics.
The method of measuring of body temperature used here
is somewhat imprecise. The result of this imprecision is
that any associations with cytokine levels will be estimated conservatively. This form of variation around the
‘true’ temperature is not differential and cannot create
a spurious association. The associations we report are
therefore unlikely to be artefacts created due to imprecise temperature measurement. However, such imprecision may mask associations or will certainly reduce
the statistical significance of true associations. Because
we see corresponding associations at different time
points between cytokine levels and temperature and parasitemia, respectively, we believe that it is unlikely that
any of the associations listed appear solely by chance.
We found that before start of treatment, fever was positively associated with plasma levels of IL-10, IL-6 and
IFN-␥. A positive association between fever and IFN-␥
has been determined in patients with P. vivax malaria
(Brown et al., 1991; Seoh et al., 2003). IFN-␥ is not
known to have direct pyretic effects but may contribute
to fever via stimulation of IL-1␤ and TNF production in
macrophages (Dinarello, 1999). IL-6 is best known for
its systemic action on the liver, causing production of
acute phase proteins and is also necessary for promoting
the fever induced by TNF and IL-1, cytokines known to
enhance the IL-6 production (Zetterstrom et al., 1998).
The body temperature did, however not, correlate with
TNF-␣ nor IL-1␤, which suggests that IFN-␥ and IL-6
might be connected with fever independently of these
cytokines in our patients.
In contrast to our findings, TNF-␣ levels have been
shown to correlate with fever in several other studies
(Grau et al., 1989; Mordmuller et al., 1997; Kwiatkowski
et al., 1993; Karunaweera et al., 1992). The reason for
this discrepancy may be that we studied children with
uncomplicated P. falciparum malaria only, while others
have included patients with severe disease or P. vivax.
Stronger associations between fever and TNF in severe
P. falciparum may result from generally higher and less
fluctuating levels. Additionally, the severe disease manifestations might in turn contribute to the fever, thus
amplifying the association.
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The positive association between the IL-6 levels and
parasitemia, indicates that the parasites perhaps could
promote fever via induction of IL-6. The lack of correlation between IFN-␥ and parasitemia suggests that other
factors than the parasite load are of importance for the
production of IFN-␥ and for its association with fever.
The importance of the host’s degree of immunity for the
production of IFN-␥ has been implied in in vitro studies
using PBMC from individuals living in areas of different
malaria endemicity (Rhee et al., 2001; Migot-Nabias et
al., 1999). Thus, while there could be a causal relationship between parasite load and fever via the production
of IL-6, the relationship between parasite load and fever
with IFN-␥ seems more complex.
IL-10 is known to down regulate the production of
pro-inflammatory cytokines like IL-1␤, TNF-␣, IL-6 and
IL-12 (Moore et al., 2001) and to act as an endogenous
antipyretic by lowering LPS-induced fever in mice (Leon
et al., 1999). However, the positive correlation between
body temperature and IL-10, IFN-␥ and IL-6 in our study
suggests a poor antipyretic effect or a limited ability
of IL-10 to balance the production of these cytokines
during malaria infection. Earlier studies show that production of higher levels of IL-10 is associated with less
effective clearance of P. falciparum parasites (Hugosson
et al., 2004; Jakobsen et al., 1996). It is also possible
that IL-10 hinders the host’s ability to clear parasites by
suppressing antigen presentation and/or enhancing activation of regulatory T or B cells. The kinetics of the
cytokine production in the present study revealed that
the production of several cytokines, especially IL-1␤ and
IL-12, increased in levels between days 2 and 3 of treatment. The reason for this is unknown but could perhaps
be a consequence of a diminished suppressive effect by
IL-10 when the levels of this cytokine decrease.
The fact that the cytokines that correlated with fever
also decreased during treatment suggests that their subsequent production may somehow be related to the
induction or the maintenance of the fever. However,
the association could alternatively be explained by a
common or parallel induction pathway for fever and
pro-inflammatory cytokines. We have previously shown
that lower mean temperatures (6–48 h) are achieved with
SP + chloroquine and SP + paracetamol compared to SP
alone or chloroquine alone (Hugosson et al., 2003).
In this study we show that these differences were not
reflected by differences in levels of any of the nine
cytokines. The antipyretic effect of chloroquine was evident already after 6 h (Hugosson et al., 2003). A close
kinetic study within that time interval might reveal if
the antipyretic effect is connected with early changes
in endopyrogenic cytokine levels or their downstream

mediators. However, the slow decrease in body temperature in the group treated with SP alone indicates
that whatever induces the fever, continues to do so
even when the parasite mass is considerably reduced.
The antipyretic effect of chloroquine therefore seems to
be long lasting and thus potential chloroquine induced
changes in cytokine levels should be expected to be
seen also at later time points. The lack of differences
in cytokine levels between the treatment groups could
depend on too large individual differences among the
patients in regard to genetics, maturity of the immune
system, age, previous exposure to malaria, and other disease related differences. Another interpretation of the
results is that chloroquine exerts its antipyretic effect at
another level than on the production of the cytokines.
Treatment with SP + paracetamol did not change the
cytokine levels compared to SP alone. This is in line with
that paracetamol is thought to suppresses the production
of PGE2 by a mechanism downstream to cytokine production (Graham and Scott, 2005). Similar effects could
be true for chloroquine.
It has recently been shown that chloroquine can
inhibit signalling through TLRs (Lee et al., 2003; Zou et
al., 2003). The vast product of malaria parasites, haemozoin, was shown to induce pro-inflammatory responses
in dendritic cells via signalling through TLR9 (Coban et
al., 2005). The inhibiting effect of chloroquine is specific for some TLRs and their differential distribution
might explain the different effects of chloroquine on different cell types (Lee et al., 2003; Park et al., 2003).
Chloroquine might therefore directly inhibit cytokine
independent fever induction via TLRs (or other receptors) in the brain, while having no short turn effect on the
plasma cytokine levels in uncomplicated P. falciparum
malaria. Whether chloroquine’s inhibiting effect on signalling pathways for TLRs has a clinical impact during
human malaria infections still remains to be elucidated.
In conclusion, our data show associations between
fever and plasma levels of IFN-␥, IL-10 and IL-6,
while the antipyretic effects of chloroquine could not be
explained by changes in production of these cytokines.
However, further studies are needed to determine at what
level in the inflammatory process chloroquine exerts its
main anti-inflammatory and antipyretic effects.
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